Study of Cytokines in Children With Opsoclonus-Myoclonus Syndrome (OMS)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00806182 |
Recruitment Status
:
Completed
First Posted
: December 10, 2008
Last Update Posted
: May 23, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Opsoclonus-myoclonus Syndrome |
Study Type : | Observational |
Actual Enrollment : | 400 participants |
Observational Model: | Case-Control |
Time Perspective: | Other |
Official Title: | Cytokines as Biomarkers and Therapeutic Targets in Paraneoplastic Opsoclonus-Myoclonus Syndrome (OMS) |
Study Start Date : | January 2008 |
Actual Primary Completion Date : | December 2016 |
Actual Study Completion Date : | December 2016 |

Group/Cohort |
---|
Pediatric case-controls
These are children who underwent lumbar puncture and blood drawing for diagnostic testing for non-inflammatory neurological or non-neurological disorders, and whose samples were retrieved from the clinical lab under a linked Institutional Review Board (IRB) protocol.
|
Pediatric OMS
These are patients treated by the P.I. based on clinical decision making, not a clinical trial (this is an observational study). The types of treatments are varied, and, on the initial evaluation, the patients may be untreated or already tried on various immunotherapies. They range from monotherapy with steroids, ACTH, or IVIg, to disease modifying agents, such as rituximab, cyclophosphamide, and other chemotherapy, typically adjunctively or as combination therapy.
|
- Reduction in inflammatory cytokines [ Time Frame: 6 and 12 months ]Reduction in the concentration of inflammatory chemokines/cytokines between clinical time points
- Correlation of cytokine concentration and clinical severity score. [ Time Frame: 6 and 12 months ]Statistical correlation of chemokine/cytokine concentration with OMS motor severity as measured using the OMS video evaluation scale
Biospecimen Retention: Samples Without DNA

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 1 Year to 18 Years (Child, Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Probability Sample |
Inclusion Criteria:
- Clinical diagnosis of OMS
Exclusion Criteria:
- Equivocal diagnosis
- Contraindications to lumbar puncture
- Treatment with agents outside the scope of the study

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00806182
United States, Illinois | |
National Pediatric Myoclonus Center, Formerly at Dept. of Neurology, Southern Illinois University School of Medicine | |
Springfield, Illinois, United States, 62702 |
Principal Investigator: | Michael R Pranzatelli, MD | National Pediatric Neuroinflammation Organization, Inc. | |
Study Director: | Elizabeth D Tate, FNP, MN | National Pediatric Neuroinflammation Organization, Inc. |
Additional Information:
Publications of Results:
Other Publications:
Responsible Party: | Michael R. Pranzatelli, M.D., Director, National Pediatric Neuroinflammation Organization, Inc. |
ClinicalTrials.gov Identifier: | NCT00806182 History of Changes |
Other Study ID Numbers: |
Thrasher Award 02826-2 |
First Posted: | December 10, 2008 Key Record Dates |
Last Update Posted: | May 23, 2017 |
Last Verified: | May 2017 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No | |
Studies a U.S. FDA-regulated Device Product: | No |
Keywords provided by Michael R. Pranzatelli, M.D., National Pediatric Neuroinflammation Organization, Inc.:
paraneoplastic neuroblastoma Kinsbourne syndrome |
autoimmune disease immunotherapy ataxia |
Additional relevant MeSH terms:
Syndrome Opsoclonus-Myoclonus Syndrome Paraneoplastic Syndromes, Nervous System Paraneoplastic Syndromes Myoclonus Ocular Motility Disorders Disease Pathologic Processes Dyskinesias Neurologic Manifestations |
Nervous System Diseases Signs and Symptoms Central Nervous System Diseases Cranial Nerve Diseases Eye Diseases Nervous System Neoplasms Neoplasms by Site Neoplasms Neurodegenerative Diseases |